Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master Rollover Study of T-DXd in Advanced or Metastatic Cancer
NCT06174987Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in cancer, metastatic cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Jan 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT06174987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06174987.